齐卢科普兰是有效的ravulizumab-耐火性全般性肌痛性肌痛症的C5 p.Arg885他的变体:一个案例报告
Yuya Itagaki1, Masahiro Iguchi2, Kasumi Hattori1
1Department of Neurology, Fukushima Medical University, 1 Hikarigaoka, Fukushima City, Fukushima, Japan.
Neuromuscular disorders : NMD
|March 2, 2026
概括
一种特定的C5基因变异可以使拉武利祖马布 (ravulizumab) 等补充抑制剂在一般化骨髓灰质炎 (gMG) 中效率降低. 切换到齐卢科普兰为患有这种变异的患者提供了显著的临床改善,突出了个性化治疗策略的必要性.
科学领域:
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
- 神经学 神经学
背景情况:
- 补充抑制有效地治疗补充介导的疾病,包括阳性夜间血红蛋白尿 (PNH) 和一般化骨髓灰质炎 (gMG).
- 某些补充成分5 (C5) 变体可以通过损害目标参与来阻碍C5抑制剂 (如eculizumab和ravulizumab) 的疗效.
- 以前的研究表明,在体外,eculizumab和ravulizumab可能无法实现完全的终端补充阻塞,这可能会影响特定C5变异患者的临床结果.
研究的目的:
- 报告第一个直接的临床证据,表明在患有特定C5变体 (c.2654G>A; p.Arg885His) 的一般化骨髓灰质炎 (gMG) 患者中,没有对ravulizumab的反应,随后对zilucoplan的反应.
- 强调补充抑制剂的变异导向选择对于优化补充介导疾病治疗结果的重要性.
主要方法:
- 一个抗乙胆受体抗体阳性gMG患者的病例报告,C5 c.2654G>A (p.Arg885His) 变异.
- 临床评估疾病活性和测量血液溶解补充活性 (CH50) 水平,在治疗拉武利祖马布和随后的齐卢科普兰.
- 基于临床结果和CH50抑制的治疗反应的比较.
主要成果:
- 患者在拉武利祖马布治疗期间表现出持续的疾病活动和仅部分抑制CH50,表明没有反应.
- 切换到针对特定表位体的C5抑制剂齐卢科普兰,导致同一天的临床改善和持续的缓解.
- 齐卢科普兰治疗导致无法检测的CH50水平,这意味着完全的终端补充物阻塞.
- 这种情况表明,gMG与C5 p.Arg885His变体相关的zilucoplan反应强,与对ravulizumab的无反应形成鲜明对比.
结论:
- 这种C5c.2654G>A (p.Arg885His) 变异可能会使gMG患者对拉武利祖马布无反应.
- 齐卢科普兰在具有这种特定C5变异的gMG患者中显示出有效的补充抑制和临床益处.
- 将CH50测试和C5基因定型纳入临床实践可以帮助确定可能对特定补充抑制剂有反应的患者,从而实现个性化治疗选择.
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...